Cadazolid Explained

Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in the elderly.[1] Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores.[2] Cadazolid progressed through to Phase III clinical trials,[1] but in its financial results for Q1 2018, Idorsia mentions that Actelion informed them that "following completion of Phase 3 data analysis of cadazolid - it has decided to discontinue the development of the compound."[3] __TOC__

Structure

The chemical structure of cadazolid combines the pharmacophores of oxazolidinone and fluoroquinolone antibiotics.[2]

Clinical trials

In a study published in the journal Anaerobe, cadazolid has been shown to be effective in vitro against 133 strains of Clostridium difficile all collected from Sweden.[4]

In phase I tests, sixty four male patients reacted favourably to cadazolid which primarily acted and remained in the colon while displaying little toxicity even in regimes involving large doses.[1]

See also

Notes and References

  1. Web site: Promising C. difficile Antibiotic in Pipeline . Boschert . Sherry . vanc . 19 September 2012 . Internal Medicine News . International Medical News Group . 22 May 2013.
  2. Web site: Cadazolid . .actelion.com . 2013-05-22 . https://web.archive.org/web/20130609070712/http://www1.actelion.com/en/scientists/development-pipeline/phase-2/cadazolid.page . 2013-06-09 . dead .
  3. Web site: Idorsia announces financial results for the first quarter 2018. April 19, 2018. Idorsia. April 27, 2018. https://web.archive.org/web/20180428011732/https://www.idorsia.com/media/news-details?newsId=2185240. April 28, 2018. dead.
  4. Rashid MU, Lozano HM, Weintraub A, Nord CE . In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden . Anaerobe . 20 . 32–5 . April 2013 . 23454525 . 10.1016/j.anaerobe.2013.02.003 .